Bicara Therapeutics (BCAX) Retained Earnings (2023 - 2026)

Bicara Therapeutics' Retained Earnings history runs 4 years deep, the most recent figure standing at -$243000.0 for Q1 2026.

• In Q1 2026, Retained Earnings rose 99.91% year-over-year to -$243000.0; the TTM figure through Mar 2026 stood at -$243000.0 (up 99.91% YoY), while the FY2025 annual figure was -$359.0 million, down 62.42% from the prior year.
• Retained Earnings for Q1 2026 stood at -$243000.0, up from -$359.0 million in the prior quarter.
• The five-year high for Retained Earnings was -$243000.0 in Q1 2026, with the low at -$359.0 million in Q4 2025.
• The 4-year median for Retained Earnings is -$239.5 million (2025), against an average of -$224.8 million.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings slumped 62.42% in 2025, then surged 99.91% in 2026.
• Bicara Therapeutics' Retained Earnings stood at -$153.0 million in 2023, then plunged by 44.44% to -$221.0 million in 2024, then plunged by 62.42% to -$359.0 million in 2025, then surged by 99.93% to -$243000.0 in 2026.
• Business Quant data shows BCAX's Retained Earnings at -$243000.0 in Q1 2026, -$359.0 million in Q4 2025, and -$321.6 million in Q3 2025.